Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis
作者:Shuhao Zhou、Weiwei Mao、Yuan Su、Xuejian Zheng、Wenyuan Qian、Meiyue Shen、Ningli Shan、Yaoshuang Li、Degang Wang、Shouting Wu、Tiemin Sun、Liwei Mu
DOI:10.1021/acs.jmedchem.2c01550
日期:2022.12.22
demonstrated the high activity and selectivity (37-fold for JAK2). At the same time, TUL01101 also demonstrated excellent metabolic stability and pharmacokinetics (PK) profiles were assayed in three species (mouse, rat, and dog). Moreover, it has been validated for effective activity in the treatment of RA both in collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) models, with low dose
Janus 激酶 1 (JAK1) 是治疗类风湿性关节炎 (RA) 的潜在靶点。在这项研究中,引入带有二氟取代的环丙酰胺的螺环导致基于 filgotinib 的三唑并 [1,5- a ] 吡啶核鉴定出 TUL01101(化合物36 )。它对具有 IC 50的 JAK1 表现出极好的效力值为 3 nM,对 JAK2 和 TYK2 的选择性超过 12 倍。全血测定也证明了高活性和选择性(JAK2 的 37 倍)。同时,TUL01101 还表现出出色的代谢稳定性,并且在三个物种(小鼠、大鼠和狗)中测定了药代动力学 (PK) 曲线。此外,它已在胶原蛋白诱导的关节炎 (CIA) 和佐剂诱导的关节炎 (AIA) 模型中验证了治疗 RA 的有效活性,具有低剂量和低毒性。目前,TUL01101已进入I期临床试验。